FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212884735> ?p ?o ?g. }

• W4212884735 endingPage "S360" @default.
• W4212884735 startingPage "S360" @default.
• W4212884735 abstract "Hepatitis C virus (HCV) infection is a major public health threat in Malaysia and haemodialysis is a known risk factor for its transmission. Sofosbuvir-based therapies were recently introduced in Malaysia to treat chronic HCV but evidence on its effectiveness to treat patients with end-stage kidney failure (ESKF) under usual clinical settings remains limited. We initiated the first effectiveness research in the country to evaluate the use of sofosbuvir-daclatasvir with or without ribavirin (SOF-DVC ± RBV) in the ESKF population to treat chronic HCV infection. This is a prospective, multi-centre observational study in ESKF patients receiving SOF-DCV ± RBV. All chronic (> 6 months) HCV infected adults aged 18 years and above currently undergoing renal replacement therapies in Malaysian public hospitals were eligible for inclusion in the study. Patient information including demographic data, HCV disease characteristics, primary renal disease, treatment details, laboratory assessments, and sustained virologic response (SVR) results were documented at intervals that matched patients’ routine clinic visits. At SVR12 and SVR24, HCV RNA results were collected to assess treatment effectiveness. A total of 113 patients from 24 hospitals were included in the cohort. Patient characteristics are shown in Table 1. Three patients dropped out; two because they could not tolerate the side effects and one for unknown reasons. A total of 58 patients have completed treatment and were observed for at least 12 weeks post-treatment. The average dose of ribavirin was 200mg three times a week, with a maximum dose of 1000mg daily. No adverse event from ribavirin use reported. All 58 patients achieved SVR12 (median 13.1 weeks (IQR 12-14)) and 100% (25 of 25) patients achieved SVR24 (median 26 weeks (IQR 24-28)). The remaining 34 patients were still under follow-up (for SVR24) at the time of analysis. One patient (1.7%) experienced a relapse at 43 weeks (HCV RNA 246015 IU/ml). Five serious adverse events were reported in four patients (2 hospitalisations, 3 deaths). None were related to the study drugs. The interim analysis suggested the SOF-DCV ± RBV was effective in treating HCV infection in patients with ESKF under the real-world scenario, resulting in an SVR12 cure rate of 100%. The treatment regimen was safe and well-tolerated. However, a longer follow-up of the patients is needed to determine if HCV can be eliminated from the micro-environment (dialysis unit) using the SOF-DCV treatment regimen." @default.
• W4212884735 created "2022-02-24" @default.
• W4212884735 creator A5016474026 @default.
• W4212884735 creator A5032313672 @default.
• W4212884735 creator A5048385801 @default.
• W4212884735 creator A5075353653 @default.
• W4212884735 creator A5088352887 @default.
• W4212884735 date "2022-02-01" @default.
• W4212884735 modified "2023-10-18" @default.
• W4212884735 title "POS-836 REAL-WORLD EFFECTIVENESS STUDY OF SOFOSBUVIR-DACLATASVIR WITH OR WITHOUT RIBAVIRIN IN TREATING CHRONICALLY INFECTED HCV PATIENTS WITH END-STAGE KIDNEY FAILURE: AN INTERIM RESULT" @default.
• W4212884735 doi "https://doi.org/10.1016/j.ekir.2022.01.873" @default.
• W4212884735 hasPublicationYear "2022" @default.
• W4212884735 type Work @default.
• W4212884735 citedByCount "0" @default.
• W4212884735 crossrefType "journal-article" @default.
• W4212884735 hasAuthorship W4212884735A5016474026 @default.
• W4212884735 hasAuthorship W4212884735A5032313672 @default.
• W4212884735 hasAuthorship W4212884735A5048385801 @default.
• W4212884735 hasAuthorship W4212884735A5075353653 @default.
• W4212884735 hasAuthorship W4212884735A5088352887 @default.
• W4212884735 hasConcept C126322002 @default.
• W4212884735 hasConcept C159047783 @default.
• W4212884735 hasConcept C197934379 @default.
• W4212884735 hasConcept C2522874641 @default.
• W4212884735 hasConcept C2776408679 @default.
• W4212884735 hasConcept C2776455275 @default.
• W4212884735 hasConcept C2776979040 @default.
• W4212884735 hasConcept C2778390639 @default.
• W4212884735 hasConcept C2778653478 @default.
• W4212884735 hasConcept C2780040827 @default.
• W4212884735 hasConcept C2908647359 @default.
• W4212884735 hasConcept C71924100 @default.
• W4212884735 hasConcept C72563966 @default.
• W4212884735 hasConcept C99454951 @default.
• W4212884735 hasConceptScore W4212884735C126322002 @default.
• W4212884735 hasConceptScore W4212884735C159047783 @default.
• W4212884735 hasConceptScore W4212884735C197934379 @default.
• W4212884735 hasConceptScore W4212884735C2522874641 @default.
• W4212884735 hasConceptScore W4212884735C2776408679 @default.
• W4212884735 hasConceptScore W4212884735C2776455275 @default.
• W4212884735 hasConceptScore W4212884735C2776979040 @default.
• W4212884735 hasConceptScore W4212884735C2778390639 @default.
• W4212884735 hasConceptScore W4212884735C2778653478 @default.
• W4212884735 hasConceptScore W4212884735C2780040827 @default.
• W4212884735 hasConceptScore W4212884735C2908647359 @default.
• W4212884735 hasConceptScore W4212884735C71924100 @default.
• W4212884735 hasConceptScore W4212884735C72563966 @default.
• W4212884735 hasConceptScore W4212884735C99454951 @default.
• W4212884735 hasIssue "2" @default.
• W4212884735 hasLocation W42128847351 @default.
• W4212884735 hasOpenAccess W4212884735 @default.
• W4212884735 hasPrimaryLocation W42128847351 @default.
• W4212884735 hasRelatedWork W2114705120 @default.
• W4212884735 hasRelatedWork W2315964890 @default.
• W4212884735 hasRelatedWork W2793782584 @default.
• W4212884735 hasRelatedWork W2797369365 @default.
• W4212884735 hasRelatedWork W2899373085 @default.
• W4212884735 hasRelatedWork W2900155941 @default.
• W4212884735 hasRelatedWork W2990662371 @default.
• W4212884735 hasRelatedWork W3000606095 @default.
• W4212884735 hasRelatedWork W3041795157 @default.
• W4212884735 hasRelatedWork W4308834824 @default.
• W4212884735 hasVolume "7" @default.
• W4212884735 isParatext "false" @default.
• W4212884735 isRetracted "false" @default.
• W4212884735 workType "article" @default.